Syros Pharmaceuticals Inc. (Nasdaq: SYRS) presented disappointing preclinical data from an ongoing Phase 1 clinical trial of SY-1365. The stock price plunged $3.92 to close at $8.45.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.